Servier's Phase III INDIGO trial investigating vorasidenib meets goals

15 March 2023

Servier, a French pharma major governed by a non-profit foundation, today revealed that the Phase III INDIGO clinical trial investigating vorasidenib in monotherapy for patients with residual or recurrent IDH mutant low-grade glioma met its primary endpoint of progression free survival (PFS) and the key secondary endpoint of time to next intervention (TTNI).

The results of the prespecified interim analysis were both statistically significant and clinically meaningful, the company pointed out.

Servier gained rights to vorasidenib along with its $2 billion acquisition of Agios Pharmaceuticals’ (Nasdaq: AGIO) oncology portfolio in 2020, when it decided to move further into the cancer therapies sector, having already bought Shire’s cancer portfolio. Servier also gained rights to Tibsovo (ivosidenib) as part of the Agios deal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK